Kodiak (KOD) Six-Month Wet AMD Data Raises the Bar for REGENXBIO (RGNX)

Kodiak Sciences (KOD) said on September 28, 2026 that its wet AMD drug Zenkuda met its Phase 3 goals, with 54% of patients reaching one injection every six months.[1][2] That six-month wet AMD result raises the durability bar for eye treatments, and gene therapies that rely on cutting injection burden could come under pressure.

What Kodiak reported

The Phase 3 DAYBREAK trial showed that Zenkuda and a second candidate, KSI-501, were both non-inferior to the standard drug aflibercept on vision improvement at one year.[2] In the Zenkuda arm, 54% of patients reached six-month dosing under strict retreatment criteria.[1][2] Kodiak plans to submit a Biologics License Application to the FDA in the fourth quarter of 2026.[1]

Kodiak closed at $89.92, up 178% from $32.35 on September 25, on 38.2 million shares against 2.28 million the prior session; market cap rose to about $5.65 billion.[3]

Peers fell the same day. Regeneron (REGN) dropped 4.5% to $752.25; Benzinga attributed the decline to the trial data.[3][4] Ocular Therapeutix (OCUL) (a sustained-release eye drug developer) fell 20.7% on 15.2 million shares, against 1.6 million the prior session. EyePoint (EYPT) fell 8.6%.[3]

Background: why injection frequency matters in wet AMD

Wet age-related macular degeneration (wet AMD) is an eye disease of older adults: abnormal vessels grow and leak beneath the retina, damaging central vision.

The standard treatment is an injection of an anti-VEGF drug into the eye to suppress those vessels. Regeneron's aflibercept (brand name Eylea) and its high-dose version, Eylea HD, are the main products. They usually need an injection every 8 to 16 weeks, indefinitely.

Frequent injections are a heavy burden for elderly patients, so competition centers on durability: how long one treatment lasts.

There are two more aggressive approaches. One is sustained release. Ocular said on September 15 that it had completed a pre-NDA meeting with the FDA for Axpaxli and planned to file in the fourth quarter.[5] EyePoint's Duravyu is in Phase 3 trials that test exactly a six-month redosing interval.[6]

The other approach is gene therapy: a single surgical procedure delivers a gene into the eye so the eye keeps producing its own anti-VEGF protein, aiming for few or no further injections over the long term.

This franchise is large for Regeneron. In 2025, U.S. sales of Eylea HD and Eylea totaled $4.38 billion, 30.6% of the company's full-year revenue of $14.34 billion.[7]

From six-month dosing to gene therapy revenue expectations

First, an approved Zenkuda would give doctors six-month dosing from an ordinary eye injection, without an implant or surgery.

Second, when doctors and payers weigh more aggressive options, gene therapy is no longer measured against drugs dosed every 8 to 16 weeks but against a six-month injection.

Third, gene therapy requires surgical delivery and carries a risk of eye inflammation. With fewer extra injections left to save, fewer patients may accept those costs, and expected peak market share for these products could fall.

Fourth, lower share expectations flow into the partnership income of developers: expected milestone payments, profit sharing and royalties all shrink.

On the incumbent side, an illustrative estimate in the research material assumes that if an approved Zenkuda took 10% of the U.S. Eylea franchise, about $440 million of revenue, roughly 3% of Regeneron's total, would be affected, starting no earlier than late 2027.[7]

Company that could be affected

REGENXBIO (RGNX) is a gene therapy company developing sura-vec, an eye gene therapy for wet AMD, with AbbVie (ABBV). Under the partnership, AbbVie paid a $370 million upfront fee, with up to $1.38 billion in further milestones. The two split U.S. profits equally, and REGENXBIO receives royalties from the mid-teens to the low twenties percent outside the U.S.[8]

In the second quarter of 2026, dosing of the first patient in a diabetic retinopathy trial of sura-vec triggered a $100 million milestone payment from AbbVie.[9] First-half revenue was $114.4 million, with $6.4 million in the first quarter and $108.0 million in the second; the milestone was about 87% of it.[3][9]

REGENXBIO sits at the end of the chain. Pivotal sura-vec data in wet AMD are expected in the fourth quarter of 2026, and those data will now be compared with a six-month injection rather than drugs dosed every 8 to 16 weeks.[10] Expectations for future milestones, the U.S. profit share and ex-U.S. royalties could come under pressure, while the near-term income statement is unaffected. It depends on whether the data open a clear gap.

The stock closed at $7.47 on September 28, up 0.9%. It is down 22.8% over one month and 25.5% over one year, with a market cap of about $493 million.[3] On August 24, the FDA placed a clinical hold on the company's separate Hunter syndrome gene therapy.[11]

What to watch

The first test comes in the fourth quarter of 2026, when Kodiak plans to file and the sura-vec wet AMD pivotal data are due in the same quarter.[1][10] Watch whether company commentary or sell-side analysis compares the sura-vec result with Zenkuda's six-month interval, and how the stock reacts if the data are clean.

Next, watch whether the FDA accepts Kodiak's filing, and whether full data presented at a retina meeting show six-month patients holding their interval into year two. Regeneron's third- and fourth-quarter call comments on physician switching and longer-interval labels are also signals.

Regeneron's share loss will not show up in Eylea sales until Zenkuda is approved, around late 2027 on a standard review, with the income-statement effect in 2028.

The chain breaks if full data show the six-month group needing frequent rescue treatment, or a safety issue such as eye inflammation or retinal vasculitis emerges; if the FDA refuses to file or issues a complete response letter, pushing launch beyond 2028; if more than 80% of sura-vec patients need no further injections at one year, keeping a wide gap over six-month dosing; or if Kodiak's drug-substance supply from contract manufacturer Lonza is constrained, or payers require patients to try Eylea biosimilars first, limiting Zenkuda to a niche.[12]

This only helps you find overlooked transmission chains. It is not a stock recommendation.

Sources

[1] Kodiak Sciences · 2026-09-28 · 8-K Ex. 99.1, DAYBREAK topline · https://www.sec.gov/Archives/edgar/data/0001468748/000119312526403481/d185059dex991.htm [2] Kabutan · 2026-09-28 · Kodiak DAYBREAK topline · https://s.kabutan.jp/news/n202609281048/ [3] Drillr · 2026-09-28 · KOD, REGN, OCUL, EYPT, RGNX prices, market caps, financials [4] Benzinga · 2026-09-28 · Regeneron Eylea feels the pinch as Kodiak advances extended dosing · https://www.benzinga.com/trading-ideas/movers/26/09/62026558/regeneron-eylea-feels-the-pinch-as-kodiak-advances-extended-dosing-for-eye-drug [5] Ocular Therapeutix · 2026-09-15 · Axpaxli pre-NDA meeting · https://www.globenewswire.com/news-release/2026/09/15/3361910/0/en/ocular-therapeutix-announces-positive-pre-nda-meeting-with-u-s-fda-for-axpaxli-in-wet-amd.html [6] Drillr · 2026-05-06 · EyePoint Q1 2026 call summary [7] Regeneron · 2026-07-30 · Q2 2026 10-Q and FY2025 10-K (U.S. Eylea sales) [8] REGENXBIO · 2024-02-27 · FY2023 10-K, AbbVie collaboration terms [9] Drillr · 2026-08-06 · REGENXBIO Q2 2026 call summary [10] Drillr · 2026-05-14 · REGENXBIO Q1 2026 call summary [11] Reuters · 2026-08-24 · FDA clinical hold on Hunter syndrome program · https://www.reuters.com/business/healthcare-pharmaceuticals/fda-places-clinical-hold-regenxbios-gene-therapy-hunter-syndrome-2026-08-24/ [12] Kodiak Sciences · 2026-06-30 · Q2 2026 10-Q, Lonza supply agreement · https://www.sec.gov/Archives/edgar/data/0001468748/000119312526349251/kod-20260630.htm